Specialist Updates 
Oncology

Metastatic melanoma: Does adding a PD-1 inhibitor to targeted therapy help?

Results of the phase 3 COMBI-i trial for progression-free survival announced
Medicom Staff writer
0
23 September 2020
Save
Please login to bookmark Close
DNA - suggesting BRAF mutation

AusDoc brings you the latest news from the European Society for Medical Oncology virtual congress 2020.

Patients with unresectable or metastatic melanoma given a programmed cell death protein 1 (PD-1) inhibitor in addition to therapies targeting BRAF and MEK inhibition did not have significantly better progression-free survival, trial results show.

Preliminary results of the phase 3 COMBI-i trial were announced at the European Society of Medical Oncology (ESMO) virtual congress 2020.

In the international trial, 532 patients with untreated unresectable or metastatic BRAF-V600 mutated melanoma were randomised 1:1 to treatment with the PD-1 inhibitor spartalizumab (440mg every four weeks) plus dabrafenib (150mg twice a day) and trametinib (2mg daily) or placebo plus dabrafenib and trametinib.

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .